HSBC Holdings PLC reaffirmed their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a report published on Wednesday. The firm currently has a GBX 1,925 ($25.32) price target on the stock.

Other analysts also recently issued research reports about the company. UBS AG set a GBX 1,600 ($21.04) price target on GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Wednesday, July 26th. Bryan, Garnier & Co reaffirmed a neutral rating and issued a GBX 1,710 ($22.49) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, September 19th. Investec cut GlaxoSmithKline plc to a hold rating and lowered their price objective for the company from GBX 1,800 ($23.67) to GBX 1,390 ($18.28) in a research report on Monday, November 6th. Liberum Capital reaffirmed a buy rating and issued a GBX 1,900 ($24.99) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, July 27th. Finally, Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline plc in a research report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of GBX 1,586.67 ($20.87).

Shares of GlaxoSmithKline plc (LON:GSK) opened at GBX 1,297.50 ($17.07) on Wednesday. GlaxoSmithKline plc has a 52 week low of GBX 1,291.50 ($16.99) and a 52 week high of GBX 1,724.50 ($22.68).

GlaxoSmithKline plc (LON:GSK) last posted its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share for the quarter, topping the consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline plc had a return on equity of 461.88% and a net margin of 17.79%.

The company also recently declared a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a dividend yield of 1.41%.

In other news, insider Simon Dingemans purchased 1,076 shares of the stock in a transaction dated Thursday, October 12th. The shares were purchased at an average cost of GBX 1,527 ($20.08) per share, with a total value of £16,430.52 ($21,610.57). Also, insider Urs Rohner purchased 473 shares of the stock in a transaction dated Wednesday, October 25th. The shares were purchased at an average cost of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). Insiders have bought a total of 1,576 shares of company stock worth $2,400,376 over the last three months.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-earns-buy-rating-from-hsbc-holdings-plc/1725530.html.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.